East Bay COVID-19 Study

300,000+ One adult in each

Who volunteered
Screening phasefor volunteers
the screening phase?
household Percent who experienced "COVID-like"

8%
(whoever had the symptoms before study entry
households invited next birthday) was
2+ symptoms
2+
invited from the following 1.2%.2%

14,350
1
12 cities (31 zip codes):
Hercules, San Pablo, El Hispanic 1
.1
%
Sobrante, Pinole, 10 1 symptom
individuals Richmond, El Cerrito,
10.1%
Albany, Kensington,
participated in Berkeley, Oakland,

61%
screening phase Piedmont, and Emeryville No COVID-like
symptoms
88.7% 0
Geographic distribution of individuals in
screening phase Female 88

"COVID-like" symptoms included: dry cough, difficulty breathing,

fever, loss of sense of taste, or loss of sense of smell.

A sample of screening respondents, with an emphasis on those

who identified as Hispanic and/or a racial minority, was
selected, and each individual was invited to participate in the
next study phase (including at-home coronavirus testing)

5,535 study participants sent at-

home coronavirus test kits
Racial identities of study participants compared to
the American Community Survey (ACS)

Age and sex distribution of study participants

1,250

1,000

750
Count

Female
Male

15% Our sample of study

500

250
participants for testing was
generally representative of
0
Hispanic the surrounding East Bay
(study region is
population.
4

25% Hispanic)
-2

-3

-4

-5

-6

-7

-8

85
18

25

35

45

55

65

75

Age (years)
 East Bay COVID-19 Study
Results of at-home coronavirus testing of 5,535 participants

2 29
Geographic distribution of individuals who tested
positive for coronavirus antibodies

Positive Antibody
virus tests positives

Characteristics of individuals who

tested positive for coronavirus
antibodies

17% 69%
Hispanic Female
2 or more Black
Race of individuals who were coronavirus antibody
positive
6.9% 10.3%
2 or more races Black 10.3%
Other 6.9%

13.8%
Other Asian
13.8%
Asian 20.7% A sensitive RT-qPCR
20.7% test for SARS-CoV-2
Round 1 testing was performed using
began in early nasal/nares swabs. A
July and lasted total anti-SARS-CoV-2
White 48.3% antibody test was
~12 weeks.
performed on dried
blood spots.

White Results indicate Round 2 started in

Collaborative Team: UC Berkeley School of
October and will be
48.3%
Public Health, Univ of Minnesota Genomics prevalence of both
completed by mid
Center, Creative Testing Solutions, and viral infection and
November. In total,
Vitalant. Funding: Open Philanthropy, Fast antibodies during the
sampling and data
Grants, Mercatus Center, UC Berkeley first observational
collection will be
period was low
Innovative Genomics Institute, UC Berkeley repeated up to 4 times,
across the study every 8-10 weeks
School of Public Health, UC San Francisco.
region (<1%). through mid 2021.